Recent updates and developments in PET imaging of prostate cancer

Steven P Rowe; Geoffrey B Johnson; Martin G Pomper; Michael A Gorin; Spencer C Behr

doi:10.1007/s00261-020-02570-y

Recent updates and developments in PET imaging of prostate cancer

Abdom Radiol (NY). 2020 Dec;45(12):4063-4072. doi: 10.1007/s00261-020-02570-y.

Authors

Steven P Rowe^{1

2}, Geoffrey B Johnson³, Martin G Pomper^{4

5}, Michael A Gorin^{4

5}, Spencer C Behr⁶

Affiliations

¹ Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. srowe8@jhmi.edu.
² The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. srowe8@jhmi.edu.
³ Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, MN, USA.
⁴ Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
⁵ The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
⁶ Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.

PMID: 32417934
DOI: 10.1007/s00261-020-02570-y

Abstract

A number of positron emission tomography (PET) radiotracers have been developed to improve the sensitivity and specificity of imaging for prostate cancer. These radiotracers include the bone-seeking agent Na¹⁸F as well as more tumor-specific compounds such as ¹¹C-choline and ¹⁸F-fluciclovine. In this review, we will discuss the advantages and disadvantages of these PET radiotracers for the imaging of men with prostate cancer across a range of clinical contexts. We will also touch upon radiotracers in late clinical development that have not gained regulatory approval, including those targeted against prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR).

Keywords: Axumin; Bombesin; Choline; Fluciclovine; GRPR; PSMA.

Publication types

Review

MeSH terms

Choline
Humans
Male
Positron-Emission Tomography*
Prostatic Neoplasms* / diagnostic imaging

Substances

Choline